Emergent BioSolutions | EBS - Operating Expenses


Emergent BioSolutions reported $555.9M in Operating Expenses for its fiscal quarter ending in June of 2023.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 272.68M 6.08M Mar/2026
Akebia Therapeutics USD 63.08M 8.26M Dec/2025
ALKERMES USD 1.75B 1.43B Mar/2026
Alnylam Pharmaceuticals USD 898.54M 66.78M Mar/2026
Amarin USD 51.48M 113K Dec/2025
ANI Pharmaceuticals USD 562.3M 344.37M Mar/2026
BioMarin Pharmaceutical USD 636.56M 39.61M Mar/2026
Coherus Biosciences USD 51.83M 2.48M Dec/2025
Emergent BioSolutions USD 555.9M 242.7M Jun/2023
Exelixis USD 359.47M 3.28M Mar/2026
Glaxosmithkline GBP 5.34B 3.83B Mar/2026
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Ionis Pharmaceuticals USD 364M 54M Mar/2026
Ironwood Pharmaceuticals USD 57.33M 8.63M Dec/2024
Lexicon Pharmaceuticals USD 20.27M 6.1M Dec/2025
Lonza CHF 2.9B 184M Jun/2025
Merck USD 18.17B 8.01B Mar/2026
Moderna USD 1.78B 242M Mar/2026
Myriad Genetics USD 212.8M 16.2M Dec/2025
Nektar Therapeutics USD 40.9M 44.19M Dec/2025
Neurocrine Biosciences USD 599.9M 22.3M Mar/2026
Pacira USD 172.75M 20.93M Mar/2026
Pfizer USD 90.1B 77.19B Mar/2026
PTC Therapeutics USD 226.66M 19.64M Mar/2026
Sanofi EUR 9.31B 1.2B Mar/2026
Sarepta Therapeutics USD 372.37M 480.65M Mar/2026
United Therapeutics USD 5.9B 5.1B Mar/2026
Vanda Pharmaceuticals USD -1.14B 1.6B Dec/2025
Xoma USD 22.84M 1.67M Sep/2024